Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in synucleinopathies
Overexpression of SNCA has been implicated in the pathogenesis of synucleinopathies, particularly Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). While PD and DLB share some clinical and pathological similarities, each disease presents distinct characteristics, including the primary af...
Main Authors: | Zhiguo Sun, Boris Kantor, Ornit Chiba-Falek |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-03-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253123003025 |
Similar Items
-
The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial
by: Luiza Jadwiga Chwiszczuk, et al.
Published: (2023-05-01) -
Sex and Age Differences in a Progressive Synucleinopathy Mouse Model
by: Jérôme Lamontagne-Proulx, et al.
Published: (2023-06-01) -
Sex differences in alpha-synucleinopathies: a systematic review
by: Kausar Raheel, et al.
Published: (2023-07-01) -
In Silico Evaluation of the Potential Association of the Pathogenic Mutations of Alpha Synuclein Protein with Induction of Synucleinopathies
by: Mohamed E. Elnageeb, et al.
Published: (2023-09-01) -
Subthalamic deep brain stimulation in Parkinson's disease with SNCA mutations: Based on the follow‐up to 10 years
by: Jinyoung Youn, et al.
Published: (2022-02-01)